The Indiana University School of Medicine Department of Neurology, under the leadership of Chair Laurie Gutmann, MD, has a rich tradition in academic neurology with a national reputation in neurological education and neuroscience research. For more than 75 years, neurologists have shaped the department as a leader in education, research and clinical care. The department, housed in the state-of-the-art Indiana University Health Neuroscience Center in downtown Indianapolis, has grown to include a faculty consisting of nearly 90 physicians, clinician scientists, and scientists who are internationally and nationally recognized specialists in neurologic health and neuroscience.
Education
Accomplished physician faculty in the Department of Neurology are deeply committed to training medical students, residents and fellows in this complex field of medicine. The residency and fellowship programs provide exceptional training for the nation's future neurologists.
Research
Through a long tradition of research in cerebrovascular disease and the collaborative work of multidisciplinary subspecialty programs, investigators in the Department of Neurology are transforming patient lives through improved prevention and treatment for neurological issues.
Clinical Care
The Department of Neurology operates within the IU Health Neuroscience Center, a state-of-the-art collaborative facility that combines the expertise of several IU School of Medicine departments. Our clinical faculty, residents and fellows work together to provide exceptional patient care.
Recent News
Researchers bring promising Alzheimer’s drug target closer to potential clinical trials
IU School of Medicine researchers aim to develop a new treatment for neurodegeneration by targeting an immune cell-specific gene associated with Alzheimer's disease.
July 14, 2025
AI in Medicine: What is your 'aha' moment?
This column is the third in a four-part series from Taeho Jo, titled "AI in Medicine: From Nobel Discoveries to Clinical Frontiers."
July 11, 2025
IU neurologist's research leads to first FDA-approved drug to treat neurofibromatosis type 1
Patients who participated in the clinical trial of the new therapy not only experienced reduction in NF1 and plexiform neurofibromas tumor volume, but also reported significant improvements in pain severity and overall health-related quality of life.
June 10, 2025
Upcoming Events
Connect with an expert
News media can schedule an interview with an IU School of Medicine faculty member by contacting our media relations team.